Insightful Word
  • Investing
  • Stock
  • Economy
  • Politics
  • Investing
  • Stock
  • Economy
  • Politics
No Result
View All Result
Insightful Word
No Result
View All Result
Home Stock

Merck KGaA shares jump as FY24 outlook reaffirmed

admin by admin
October 17, 2024
in Stock
0
Merck KGaA shares jump as FY24 outlook reaffirmed
0
SHARES
13
VIEWS
Share on FacebookShare on Twitter

Investing.com — Shares of Merck KGaA surged after the company confirmed its outlook for fiscal year 2024 and revisions to its mid-term sales projections, particularly for its Life Science and Electronics divisions.

At 7:50 am (1150 GMT), Merck was trading 6.1% higher at €163.55.

Analysts at Jefferies noted that the company’s reaffirmation of its FY24 guidance, which aligns with consensus estimates, reassured investors amid ongoing uncertainties in the healthcare sector.

“Therefore at the group level we see the new guidance implying mid-term growth or around 4% which largely underpins Consensus in 2027 of €24.4bn (implied mid point €24.2bn) and thus we see this guidance as likely reassuring to investors,” said analysts at JP Morgan. 

Merck narrowed its mid-term sales growth target for the Life Science division to a range of 7% to 9% annually, down slightly from the previous 7% to 10% forecast. 

The adjustment reflects a more conservative view on the company’s prospects in China, which has seen slower growth. While this was largely anticipated, it is in line with market expectations. 

The decision to remove the 10% upper limit did not surprise analysts, as the company had hinted at this shift in earlier commentary. 

As per Jefferies, the Street had already priced in this slowdown, leaving limited room for upside surprises in the near term.

Electronics, on the other hand, saw its mid-term sales guidance upgraded to 5% to 9%, from a prior estimate of 3% to 6%. 

The semiconductor solutions segment continues to be a key driver, expected to represent 80% of Electronics sales by the end of 2025. 

This shift bolsters Merck’s growth outlook in the division, with analysts expecting a 10% year-on-year growth for semiconductor solutions in 2025, positioning it at the higher end of the updated guidance.

The Healthcare division’s forecast remains more cautious. Following recent setbacks in key drug trials, including the failure of xevinapant and evobrutinib in Phase 3 trials, Merck now expects only “slight growth” in the mid-term, rather than the previously anticipated low-single-digit range. 

However, the company remains focused on rebuilding its pipeline through increased in-licensing of drug candidates and is aiming to return to mid-single-digit growth following the U.S. loss of exclusivity for its multiple sclerosis drug Mavenclad in 2026.

Merck’s reiteration of its FY24 sales, EBITDA, and earnings guidance, all of which fall in line with market expectations, was another key driver of investor confidence. 

The company has indicated that M&A, particularly in Life Sciences, will remain a priority as it seeks to bolster its portfolio in healthcare.

This post appeared first on investing.com

Previous Post

US weekly jobless claims unexpectedly fall

Next Post

Morgan Stanley hikes price targets on networking equipment stocks

admin

admin

Next Post
Morgan Stanley hikes price targets on networking equipment stocks

Morgan Stanley hikes price targets on networking equipment stocks

Trending News

Long AMR: oversold recovery with breakout potential amid rising steel demand and strategic developments

Long AMR: oversold recovery with breakout potential amid rising steel demand and strategic developments

January 15, 2025
How high energy taxes are adding to industries’ woes in Europe?

How high energy taxes are adding to industries’ woes in Europe?

December 23, 2024
FTSE 100 index forecast as the GBP/USD exchange rate soars

FTSE 100 index forecast as the GBP/USD exchange rate soars

April 16, 2025
Subscribe to Insightful Word


    Recent News

    Hyperliquid (HYPE) hits $50 ATH as institutional adoption accelerates

    Hyperliquid (HYPE) hits $50 ATH as institutional adoption accelerates

    August 27, 2025
    Webull stock price is in a deep slumber: will it wake up after earnings?

    Webull stock price is in a deep slumber: will it wake up after earnings?

    August 27, 2025
    Wall Street braces as Nvidia earnings test AI boom and China risks

    Wall Street braces as Nvidia earnings test AI boom and China risks

    August 27, 2025
    US stocks open flat ahead of Nvidia earnings: Dow up 25 pts, Nasdaq slips 0.1%

    US stocks open flat ahead of Nvidia earnings: Dow up 25 pts, Nasdaq slips 0.1%

    August 27, 2025

    Recent News

    Hyperliquid (HYPE) hits $50 ATH as institutional adoption accelerates

    Hyperliquid (HYPE) hits $50 ATH as institutional adoption accelerates

    August 27, 2025
    Webull stock price is in a deep slumber: will it wake up after earnings?

    Webull stock price is in a deep slumber: will it wake up after earnings?

    August 27, 2025

    Latest News

    • Hyperliquid (HYPE) hits $50 ATH as institutional adoption accelerates
    • Webull stock price is in a deep slumber: will it wake up after earnings?
    • Wall Street braces as Nvidia earnings test AI boom and China risks

    About Insightful Word

    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools
    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools

    Copyright © 2025 Insightfulword.com. All Rights Reserved.

    No Result
    View All Result
    • Investing
    • Stock
    • Economy
    • Politics

    Copyright © 2025 Insightfulword.com. All Rights Reserved.